{"id":432729,"title":"Biologic drugs (Schedule D drugs) – Division 4 proposed regulatory amendments: Notice to stakeholders - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-02","captureTimestamp":"2026-01-02T08:44:01.651000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/programs/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices/biologic-drugs-schedule-d-division-4-proposed-regulatory-amendments-notice.html","snippet":"Biologic drugs (Schedule D drugs) – Division 4 proposed regulatory amendments: Notice to stakeholders A public consultation on proposed amendments to modify Division 4 in Part C of the Food and Drug Regulations (FDR) for biologic drugs was held from December 2022 to April 2023. A…","rawSnapshotUrl":"/api/snapshots/raw/432729","browseUrl":"https://replay.healtharchive.ca/job-6/20260102084401/https://www.canada.ca/en/health-canada/programs/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices/biologic-drugs-schedule-d-division-4-proposed-regulatory-amendments-notice.html#ha_snapshot=432729","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}